Phase 1, Solid Tumor, Adult
Conditions
Keywords
tropomyosin receptor kinase, Solid organ malignancies
Brief summary
This study is a first-in-human (FIH) study which is required to understand the PK characteristics, MTD, and safety profile of NOV1601(CHC2014) in subjects with solid organ malignancies.
Detailed description
This is the first-in-human, Phase 1, open-label, multicenter, dose-escalation study to investigate the safety, tolerability, PK, and clinical activity of NOV1601(CHC2014) in subjects with solid organ malignancies. The primary goal of the study is to determine the RP2D of NOV1601(CHC2014) in adult subjects with solid organ malignancies. Dose escalation will follow a 3+3 design and will be based on prior cohort review. There will be 2 branches of the dosing schedule, once a day(QD) and twice daily(BID).
Interventions
DRUGNOV1601(CHC2014)
a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A (TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
Sponsors
CMG Pharmaceutical Co. Ltd
Handok Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
(partial): * Pathological confirmation of malignancy and evidence of metastatic or surgically unresectable disease * At least one evaluable or measurable lesion should be present and identified according to Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1 or Response Assessment in Neuro-Oncology(RANO) * Relapse after or refractory to systemic drug therapy to malignancy, at least one regimen of cytotoxic chemotherapy, kinase inhibitors including tyrosine kinase inhibitors or immunotherapy which is considered as standard of care if there is no standard regimen recommended, then no experience of systemic drug therapy is acceptable * Patients with primary central nervous system(CNS) tumors or metastasis, if they have been neurologically stable * Symptoms should be under control by stable dose of glucocorticoids and analgesic drugs for symptom control at least 2 weeks prior to starting the treatment * Stable dose of glucocorticoids and analgesic drugs for symptom control should be maintained throughout the study * Subjects should be off from radiotherapy for at least 14 days prior to the start of study treatment(C1D1) without symptom aggravation
Exclusion criteria
(partial): * Prior high-dose chemotherapy requiring hematopoietic stem cell transplantation * History or evidence of suspicious leptomeningeal disease * Previous surgery of gastrectomy, gastrostomy or any medical condition which interferes with oral ingestion of capsule * Indwelling percutaneous drainage of bile and chest tube * Evidence of or suspicious symptomatic spinal cord compression, unless appropriately treated and neurologically stable off glucocorticoid for at least 2 weeks
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the recommended Phase 2 dose(RP2D) or the maximum tolerated dose(MTD) of NOV1601 | Subjects will be treated and observed for dose-limiting toxicity(DLT) through the end of the first cycle (Days 1-28). | MTD will be the RP2D, based on the pharmacokinetic(PK) profiles and safety profiles as assessed by the Safety Monitoring Committee (SMC). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events(TEAE) and serious adverse events(SAE) | Maximum 2 years | Each adverse event will be coded using the Medical Dictionary for Regulatory Activities(version 20.0) classification system. The severity of the toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. |
Countries
South Korea
Outcome results
None listed